Bruce Dale Broussard
Summary
Bruce Dale Broussard has served as HP Inc.'s interim CEO and a director since February 3, 2026, after more than a decade leading Humana.
Biography
Broussard joined HP's board in 2021 and became interim CEO after Enrique Lores stepped down on February 2, 2026. The board appointed him while it conducts a search for a permanent chief executive. ([sec.gov](https://www.sec.gov/Archives/edgar/data/47217/000114036126003514/ef20064653_ex99-1.htm?utm_source=openai)) Before joining HP's operating leadership, Broussard was president and CEO of Humana for more than a decade. Humana credits him with leading a multi-year digital and analytics transformation. Before Humana, he held several senior roles at US Oncology, including chief financial officer, president, CEO, and chairman. ([hp.com](https://www.hp.com/content/dam/sites/garage-press/press/press-kits/2026/hp-imagine/Bruce%20Broussard%20Bio.pdf?utm_source=openai)) He has more than 30 years of experience in public companies, healthcare, international business management, and technology-enabled transformation. His background is primarily in healthcare rather than personal-computer or printing businesses. ([hp.com](https://www.hp.com/content/dam/sites/garage-press/press/press-kits/2026/hp-imagine/Bruce%20Broussard%20Bio.pdf?utm_source=openai))
Notable achievements
- Led Humana through a multi-year digital and analytics transformation. ([hp.com](https://www.hp.com/content/dam/sites/garage-press/press/press-kits/2026/hp-imagine/Bruce%20Broussard%20Bio.pdf?utm_source=openai))
- Held CEO, CFO, president, and chairman roles at US Oncology before its acquisition by McKesson. ([hp.com](https://www.hp.com/us-en/newsroom/press-releases/2021/hp-names-bruce-broussard-to-board-of-directors.html?utm_source=openai))
- Provided continuity at HP after the February 2026 leadership change and helped maintain the company's stated strategic priorities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/47217/000114036126003514/ef20064653_ex99-1.htm?utm_source=openai))
- During his interim tenure, HP introduced new AI PCs, security products, AI-powered printing offerings, and workflow tools at HP Imagine 2026. ([hp.com](https://www.hp.com/us-en/newsroom/press-releases/2026/hp-reimagines-future-of-work.html?utm_source=openai))
Problem areas / controversies
- Humana received a $3.1 million civil monetary penalty from CMS in 2015 for Medicare Advantage and prescription-drug-plan compliance deficiencies while Broussard was CEO. ([cms.gov](https://www.cms.gov/medicare/compliance-and-audits/part-c-and-part-d-compliance-and-audits/downloads/humana_cmp_12_29_2015.pdf?utm_source=openai))
- The Justice Department has alleged that Humana and other insurers used improper broker incentives in Medicare Advantage enrollment; the complaint also cited Broussard's awareness of complaints and aggressive sales practices. These are allegations in ongoing litigation, not a finding that Broussard personally committed wrongdoing. ([justice.gov](https://www.justice.gov/usao-ma/pr/united-states-files-complaint-against-several-national-health-insurance-companies-and?utm_source=openai))
- His HP record is still limited because he is serving in an interim role, and the company continues to face industry-wide memory-cost, supply-chain, and printing-demand pressures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/47217/000004721726000011/hpq-20260131.htm?utm_source=openai))